These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 32409880)

  • 21. X-Linked Hypophosphatemia: A New Era in Management.
    Dahir K; Roberts MS; Krolczyk S; Simmons JH
    J Endocr Soc; 2020 Dec; 4(12):bvaa151. PubMed ID: 33204932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene.
    Saito T; Nishii Y; Yasuda T; Ito N; Suzuki H; Igarashi T; Fukumoto S; Fujita T
    Eur J Endocrinol; 2009 Oct; 161(4):647-51. PubMed ID: 19581284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rickets guidance: part II-management.
    Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
    Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of X-linked hypophosphatemia in adults.
    Lecoq AL; Brandi ML; Linglart A; Kamenický P
    Metabolism; 2020 Feb; 103S():154049. PubMed ID: 31863781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
    Carpenter TO; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Wooddell MM; Kawakami T; Ito T; Zhang X; Humphrey J; Insogna KL; Peacock M
    J Clin Invest; 2014 Apr; 124(4):1587-97. PubMed ID: 24569459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
    Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGF23 and its role in X-linked hypophosphatemia-related morbidity.
    Beck-Nielsen SS; Mughal Z; Haffner D; Nilsson O; Levtchenko E; Ariceta G; de Lucas Collantes C; Schnabel D; Jandhyala R; Mäkitie O
    Orphanet J Rare Dis; 2019 Feb; 14(1):58. PubMed ID: 30808384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. X-linked hypophosphatemia: Management and treatment prospects.
    Lambert AS; Zhukouskaya V; Rothenbuhler A; Linglart A
    Joint Bone Spine; 2019 Nov; 86(6):731-738. PubMed ID: 30711691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH).
    Rothenbuhler A; Schnabel D; Högler W; Linglart A
    Metabolism; 2020 Feb; 103S():153892. PubMed ID: 30928313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
    Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approach to Hypophosphatemic Rickets.
    Ackah SA; Imel EA
    J Clin Endocrinol Metab; 2022 Dec; 108(1):209-220. PubMed ID: 35981346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
    Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
    Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired Growth Plate Maturation in XLH Is due to Both Excess FGF23 and Decreased 1,25-Dihydroxyvitamin D Signaling.
    Yadav PS; Kobelski MM; Martins JS; Tao T; Liu ES; Demay MB
    Endocrinology; 2023 Nov; 165(1):. PubMed ID: 38066669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular and Molecular Alterations Underlying Abnormal Bone Growth in X-Linked Hypophosphatemia.
    Fuente R; García-Bengoa M; Fernández-Iglesias Á; Gil-Peña H; Santos F; López JM
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Burosumab: Current status and future prospects.
    Goyal A; Tandon N
    Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101826. PubMed ID: 37858479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
    Balani S; Perwad F
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.
    Igaki JM; Yamada M; Yamazaki Y; Koto S; Izawa M; Ariyasu D; Suzuki E; Hasegawa H; Hasegawa Y
    Endocr J; 2011; 58(8):647-55. PubMed ID: 21597229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of X-Linked Hypophosphatemia on Muscle Symptoms.
    Romagnoli C; Iantomasi T; Brandi ML
    Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.